Cancer Advisor

Medically Reviewed by: OneDayMD Editorial Team | Written by:     Dr Frank Yap, MD | Last Updated:   August  8, 2026 Can ivermectin, mebendazole, fenbendazole or niclosamide overcome Tagrisso resistance? These repurposed drugs have generated interest because some affect signaling pathways involved in cancer-cell survival and drug resistance. However, the current evidence does not establish any of them as clinically proven treatments for osimertinib-resistant EGFR-mutated lung cancer. Tagrisso (osimertinib) is a third-generation EGFR tyrosine kinase inhibitor used extensively for EGFR-mutated non-small-cell lung cancer (NSCLC). Although osimertinib can produce prolonged disease control, acquired resistance eventually develops in most patients with advanced disease. Key takeaway: The scientifically strongest approach to Tagrisso resistance is not to empirically add several repurposed drugs. It is to identify the resistance mechanism through molecular profili...

Skip to main content OneDayMD  ›  Cancer Academy  ›  Lung Cancer & NSCLC  ›  EGFR-Positive NSCLC OneDayMD Cancer Academy A patient-first guide to EGFR-mutated non-small cell lung cancer (NSCLC), targeted therapy, treatment response, acquired resistance, progression, biomarker retesting, brain metastases, and treatment options after resistance. The most important idea: EGFR-positive lung cancer is not one static disease. The molecular profile of a tumor can change over time, particularly when treatment creates evolutionary pressure. When cancer progresses, the next question is often not simply “What drug should I take?” but “What has changed biologically, and what evidence do we have?” This Academy page is designed to help patients and families understand the logic of modern precision oncology and prepare better questions for their oncology team. It d...

Different cancers behave differently because they are driven by different genetic mutations . The same gene (like KRAS or TP53) can mean very different things depending on whether it appears in lung, colon, or pancreatic cancer . This guide translates those patterns into a clear, patient-focused mutation map . 1. Lung Cancer (NSCLC): The most mutation-driven solid tumor Non-small cell lung cancer (NSCLC) is one of the most genetically profiled cancers in the world. Treatment is now heavily guided by mutation testing. Key mutations in lung cancer EGFR (most clinically actionable) One of the most important mutations in lung adenocarcinoma More common in: Non-smokers Women Asian populations What it means: Tumor growth is driven by an overactive EGFR signaling pathway Cancer depends heavily on this “growth antenna” Treatment implication: Highly responsive to EGFR-targeted therapies Often first-line treatment in EGFR-positive disease Examples include EGFR tyrosine kinase inhibitors Patient ...